UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 148

Sortiert nach

Consensus-based recommendations for the management of juvenile localised scleroderma

Annals of the rheumatic diseases, 2019-08, Vol.78 (8), p.1019

2019

Volltextzugriff (PDF)

Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study

Arthritis & rheumatology (Hoboken, N.J.), 2020-12, Vol.72 (12), p.2147-2158

2020

Volltextzugriff (PDF)

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

The New England journal of medicine, 2012-12, Vol.367 (25), p.2396-2406

2012

Volltextzugriff (PDF)

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes

The New England journal of medicine, 2018-05, Vol.378 (20), p.1908-1919

2018

Volltextzugriff (PDF)

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Arthritis research & therapy, 2019-05, Vol.21 (1), p.125-125, Article 125

2019

Volltextzugriff (PDF)

Vaccination proposal for patients on onasemnogene abeparvovec therapy

European journal of paediatric neurology, 2024-03, Vol.49, p.95-99

2024

Volltextzugriff (PDF)

Multisystem inflammatory syndrome in children (MIS-C): Implications for long COVID

Inflammopharmacology, 2023-10, Vol.31 (5), p.2221-2236

2023

Volltextzugriff (PDF)

Development of minimum standards of care for juvenile localized scleroderma

European journal of pediatrics, 2018-07, Vol.177 (7), p.961-977

2018

Volltextzugriff (PDF)

Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study

Journal of rheumatology, 2008-03, Vol.35 (3), p.438

2008

Volltextzugriff (PDF)

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis

Rheumatic & musculoskeletal diseases open, 2022-03, Vol.8 (1), p.e002042

2022

Volltextzugriff (PDF)

COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients

Expert reviews in molecular medicine, 2022-03, Vol.24, p.e13-e13, Article e13

2022

Volltextzugriff (PDF)

Proposed Response Parameters for Twelve‐Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings

Arthritis care & research (2010), 2023-12, Vol.75 (12), p.2453-2462

2023

Volltextzugriff (PDF)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use

Rheumatology (Oxford, England), 2022-05, Vol.61 (5), p.2104-2112

2022

Volltextzugriff (PDF)

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

Arthritis research & therapy, 2020-04, Vol.22 (1), p.71-15, Article 71

2020

Volltextzugriff (PDF)

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

Annals of the rheumatic diseases, 2013-05, Vol.72 (5), p.678-685

2013

Volltextzugriff (PDF)

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative

Annals of the rheumatic diseases, 2017-05, Vol.76 (5), p.782

2017

Volltextzugriff (PDF)

Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022

Expert review of clinical immunology, 2024-04, Vol.20 (4), p.387-404

2024

Volltextzugriff (PDF)

Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients

The clinical respiratory journal, 2017-11, Vol.11 (6), p.942-950

2017

Volltextzugriff (PDF)

Paraneoplastic myopathy

Current opinion in rheumatology, 2009-11, Vol.21 (6), p.594-598

2009

Volltextzugriff (PDF)

The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

Rheumatology international, 2018-04, Vol.38 (Suppl 1), p.243-250

2018

Volltextzugriff (PDF)

Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

Pediatric rheumatology online journal, 2019-08, Vol.17 (1), p.57-57, Article 57

2019

Volltextzugriff (PDF)

Educational initiatives and training for paediatric rheumatology in Europe

Pediatric rheumatology online journal, 2018-12, Vol.16 (1), p.77-77, Article 77

2018

Volltextzugriff (PDF)

Correction to: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)

Pediatric rheumatology online journal, 2020-02, Vol.18 (1), p.14-14, Article 14

2020

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(110)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(93)
Life Sciences & Biomedicine
(73)
Humans
(66)
Rheumatology
(46)
Child
(43)
Female
(37)
Male
(33)
Adolescent
(28)
Pediatrics
(27)
Child, Preschool
(21)
Technology
(20)
Engineering
(19)
Patients
(19)
Adult
(16)
Treatment Outcome
(16)
Arthritis
(14)
Arthritis, Juvenile - Drug Therapy
(14)
Antirheumatic Agents - Therapeutic Use
(12)
Europe
(10)
Engineering, Multidisciplinary
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Consensus-based recommendations for the management of juvenile localised scleroderma

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial

Vaccination proposal for patients on onasemnogene abeparvovec therapy

Multisystem inflammatory syndrome in children (MIS-C): Implications for long COVID

Development of minimum standards of care for juvenile localized scleroderma

Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis

COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients

Proposed Response Parameters for Twelve‐Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022

Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)

Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients

Paraneoplastic myopathy

The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

Educational initiatives and training for paediatric rheumatology in Europe

Correction to: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)

Suchergebnisse filtern